-
Business
2023.01.05
Issuance of Key Patent Covering Novel Nrf2 Activator
-
Paper
2022.10.14
Publication of a clinical phase 2 study of SCO-792
-
Business
2022.06.27
Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activator
Page Top